Cargando…

24h-gene variation effect of combined bevacizumab/erlotinib in advanced non-squamous non-small cell lung cancer using exon array blood profiling

BACKGROUND: The SAKK 19/05 trial investigated the safety and efficacy of the combined targeted therapy bevacizumab and erlotinib (BE) in unselected patients with advanced non-squamous non-small cell lung cancer (NSCLC). Although activating EGFR mutations were the strongest predictors of the response...

Descripción completa

Detalles Bibliográficos
Autores principales:	Baty, Florent, Joerger, Markus, Früh, Martin, Klingbiel, Dirk, Zappa, Francesco, Brutsche, Martin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2017
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5372268/ https://www.ncbi.nlm.nih.gov/pubmed/28359318 http://dx.doi.org/10.1186/s12967-017-1174-z

Ejemplares similares

EGFR Exon-Level Biomarkers of the Response to Bevacizumab/Erlotinib in Non-Small Cell Lung Cancer
por: Baty, Florent, et al.
Publicado: (2013)

Non-pharmaceutical interventions to optimize cancer immunotherapy
por: Boesch, Maximilian, et al.
Publicado: (2023)

Local tumor microbial signatures and response to checkpoint blockade in non-small cell lung cancer
por: Boesch, Maximilian, et al.
Publicado: (2021)

Tumour neoantigen mimicry by microbial species in cancer immunotherapy
por: Boesch, Maximilian, et al.
Publicado: (2021)

Efficacy and safety of bevacizumab plus erlotinib versus bevacizumab or erlotinib alone in the treatment of non-small-cell lung cancer: a systematic review and meta-analysis
por: Zhang, Shu, et al.
Publicado: (2016)

Docetaxel-carboplatin in combination with erlotinib and/or bevacizumab in patients with non-small cell lung cancer
por: Boutsikou, Eftimia, et al.
Publicado: (2013)

Epidermal Growth Factor Receptor Mutation in a Patient with Squamous Cell Carcinoma of the Lung: Who Should Be Tested?
por: Schwitter, Michael, et al.
Publicado: (2013)

In-Hospital Disease Burden of Sarcoidosis in Switzerland from 2002 to 2012
por: Pohle, Susanne, et al.
Publicado: (2016)

Bevacizumab plus erlotinib versus erlotinib alone for advanced EGFR-mutant non-small cell lung cancer: a meta-analysis of randomized clinical trials
por: Li, Ruijian, et al.
Publicado: (2023)

Comparing Efficacy of Erlotinib and Bevacizumab Combination with Erlotinib Monotherapy in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC): A Systematic Review and Meta-Analysis
por: Sakharkar, Prashant, et al.
Publicado: (2023)

Impact of EMT in stage IIIB/IV NSCLC treated with erlotinib and bevacizumab when compared with cisplatin, gemcitabine and bevacizumab
por: Villalobos, Matthias, et al.
Publicado: (2019)

Design paper: A phase II study of Bevacizumab and Erlotinib in patients with non-Squamous non-small cell lung cancer that is refractory or relapsed after 1-2 previous Treatment (BEST)
por: Tanaka, Shiro, et al.
Publicado: (2011)

Phase I/II study of erlotinib, carboplatin, pemetrexed, and bevacizumab in chemotherapy-naïve patients with advanced non-squamous non-small cell lung cancer harboring epidermal growth factor receptor mutation
por: Kurata, Takayasu, et al.
Publicado: (2017)

Efficacy and Safety of Bevacizumab Plus Erlotinib in Patients with Renal Medullary Carcinoma
por: Wiele, Andrew J., et al.
Publicado: (2021)

Erlotinib plus bevacizumab versus erlotinib alone in patients with EGFR-positive advanced non-small-cell lung cancer: a systematic review and meta-analysis of randomised controlled trials
por: Deng, Wusheng, et al.
Publicado: (2022)

Addition of bevacizumab enhances antitumor activity of erlotinib against non-small cell lung cancer xenografts depending on VEGF expression
por: Li, Heyan, et al.
Publicado: (2014)

Efficacy and safety of erlotinib combined with bevacizumab in the treatment of non-small cell lung cancer: A systematic review and meta-analysis
por: Zhou, Kenan, et al.
Publicado: (2020)

Sputum DNA sequencing in cystic fibrosis: non-invasive access to the lung microbiome and to pathogen details
por: Feigelman, Rounak, et al.
Publicado: (2017)

Comorbidities and Burden of COPD: A Population Based Case-Control Study
por: Baty, Florent, et al.
Publicado: (2013)

Identification of smoking cessation phenotypes as a basis for individualized counseling: An explorative real-world cohort study
por: Paciorkowski, Maciej, et al.
Publicado: (2022)

In-hospital survival paradox in patients with sleep apnea—A nation-wide nested case-control study
por: Moser, Maurice, et al.
Publicado: (2022)

Fumarate hydratase-deficient renal cell carcinoma in extended remission with bevacizumab and erlotinib
por: Tomar, Shubham, et al.
Publicado: (2022)

Gene Expression and Isoform Variation Analysis using Affymetrix Exon Arrays
por: Bemmo, Amandine, et al.
Publicado: (2008)

Gene expression and isoform variation analysis using Affymetrix exon arrays
por: Bemmo, Amandine, et al.
Publicado: (2009)

The Clinical Impact of Methylated Homeobox A9 ctDNA in Patients with Non-Resectable Biliary Tract Cancer Treated with Erlotinib and Bevacizumab
por: Andersen, Line Bechsgaard, et al.
Publicado: (2022)

Stability of gene contributions and identification of outliers in multivariate analysis of microarray data
por: Baty, Florent, et al.
Publicado: (2008)

Analysis with respect to instrumental variables for the exploration of microarray data structures
por: Baty, Florent, et al.
Publicado: (2006)

Modeling the oxygen uptake kinetics during exercise testing of patients with chronic obstructive pulmonary diseases using nonlinear mixed models
por: Baty, Florent, et al.
Publicado: (2016)

Gender-specific disease trajectories prior to the onset of COPD allow individualized screening and early intervention
por: Hagmann, Michelle, et al.
Publicado: (2023)

Comparison of Affymetrix Gene Array with the Exon Array shows potential application for detection of transcript isoform variation
por: Ha, Kevin CH, et al.
Publicado: (2009)

Pemetrexed/Carboplatin/Bevacizumab followed by Maintenance Pemetrexed/Bevacizumab in Hispanic Patients with Non-Squamous Non-Small Cell Lung Cancer: Outcomes according to Thymidylate Synthase Expression
por: Cardona, Andrés Felipe, et al.
Publicado: (2016)

Bevacizumab counteracts VEGF-dependent resistance to erlotinib in an EGFR-mutated NSCLC xenograft model
por: Masuda, Chinami, et al.
Publicado: (2017)

Erlotinib Plus Bevacizumab Phase ll Study in Patients with Advanced Non-small-Cell Lung Cancer (JO25567): Updated Safety Results
por: Kato, Terufumi, et al.
Publicado: (2017)

Safety and Patient-Reported Outcomes of Atezolizumab Plus Chemotherapy With or Without Bevacizumab Versus Bevacizumab Plus Chemotherapy in Non–Small-Cell Lung Cancer
por: Reck, Martin, et al.
Publicado: (2020)

Exploring the transcription factor activity in high-throughput gene expression data using RLQ analysis
por: Baty, Florent, et al.
Publicado: (2013)

Diagnostic precision and identification of rare diseases is dependent on distance of residence relative to tertiary medical facilities
por: Walter, Anna-Lena, et al.
Publicado: (2021)

Getting out of a wheelchair: an uncommon insertion mutation in exon 19 of EGFR responsive to erlotinib
por: Agbarya, Abed, et al.
Publicado: (2014)

Erlotinib-based doublet targeted therapy versus erlotinib alone in previously treated advanced non-small-cell lung cancer: a meta-analysis from 24 randomized controlled trials
por: Gao, Jian-Wei, et al.
Publicado: (2017)

Comparison of efficacy and safety of bevacizumab biosimilar and original bevacizumab in non-squamous non-small cell lung cancer: a systematic review and meta-analysis
por: Xiao, Xian, et al.
Publicado: (2022)

Carcinoma of Unknown Primary Site Treated with Carboplatin + Paclitaxel + Bevacizumab + Erlotinib and Its Maintenance Chemotherapy
por: Yasui, Hirotoshi, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_2bv8i4nc46u5pmu67l73tohnb1